Sugenoya A, Kidd A, Row V V, Volpé R
J Clin Endocrinol Metab. 1979 Mar;48(3):398-402. doi: 10.1210/jcem-48-3-398.
Several reports have been published on the anti-TSH receptor antibody in putative autoimmune thyroid disorders using a radioreceptor assay. We have carried out correlative studies between the ability of serum immunoglobulins to displace radiolabeled TSH from the thyroid plasma membrane receptor [TSH-displacing activity (TDA)] and that of actual stimulation of the human thyroid gland [human thyroid-stimulating activity (hTSA)] in Graves' and other thyroid diseases and in control subjects. TDA was assayed by the use of a radioligand technique, while the activation of adenylate cyclase in human thyroid slices was measured as an index of hTSA. The same immunoglobulins were employed for both assays. In this series, positive TDA and hTSA values were found in 70.4% and 81.5% of the samples in active untreated Graves' disease, respectively. Samples from normal persons and from several patients with toxic nodular goiter gave generally negative results in both assays; in a small proportion of patients with either subacute thyroiditis or Hashimoto's thyroiditis, the TDA was positive but hTSA proved to be negative. In Graves' disease (including those patients on propylthiouracil) in remission and treated with 131I, the correlation between TDA and hTSA was not significant (r = 0.309; P greater than 0.1); even when the procedures were compared in the untreated group alone, there was no significant correlation between the two activities (r = 0.309, P greater than 0.1). These studies indicate that 1) significant TDA and hTSA are observed in Graves' disease; nevertheless, the correlation between them is not significant; 2) the hTSA assay appears to be more sensitive and specific than the TDA assay; and 3) TDA may not be synonymous with thyroid stimulation.
已有多篇报告运用放射受体分析法,对疑似自身免疫性甲状腺疾病中的抗促甲状腺激素(TSH)受体抗体展开研究。我们针对格雷夫斯病及其他甲状腺疾病患者和对照受试者,开展了血清免疫球蛋白从甲状腺质膜受体置换放射性标记TSH的能力[TSH置换活性(TDA)]与实际刺激人甲状腺的能力[人甲状腺刺激活性(hTSA)]之间的相关性研究。TDA采用放射性配体技术进行测定,而人甲状腺切片中腺苷酸环化酶的激活则作为hTSA的指标进行测量。两种测定均使用相同的免疫球蛋白。在该系列研究中,未经治疗的活动性格雷夫斯病样本中,分别有70.4%和81.5%的样本TDA和hTSA值呈阳性。正常人及部分毒性结节性甲状腺肿患者的样本在两种测定中通常均呈阴性;一小部分亚急性甲状腺炎或桥本甲状腺炎患者,TDA呈阳性,但hTSA为阴性。处于缓解期且接受131I治疗的格雷夫斯病患者(包括服用丙硫氧嘧啶的患者),TDA与hTSA之间无显著相关性(r = 0.309;P>0.1);即便仅在未治疗组中比较这两种检测方法,两种活性之间也无显著相关性(r = 0.309,P>0.1)。这些研究表明:1)格雷夫斯病中可观察到显著的TDA和hTSA,但二者之间无显著相关性;2)hTSA检测似乎比TDA检测更敏感、更具特异性;3)TDA可能并非甲状腺刺激的同义词。